89 related articles for article (PubMed ID: 7541291)
1. Protection of a T-cell line from human immunodeficiency virus replication by the stable expression of a short antisense RNA sequence carried by a shuttle RNA molecule.
Cagnon L; Cucchiarini M; Lefebvre JC; Doglio A
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Aug; 9(4):349-58. PubMed ID: 7541291
[TBL] [Abstract][Full Text] [Related]
2. Intracellular expression of antisense RNA transcripts complementary to the human immunodeficiency virus type-1 vif gene inhibits viral replication in infected T-lymphoblastoid cells.
Barnor JS; Miyano-Kurosaki N; Yamaguchi K; Sakamoto A; Ishikawa K; Inagaki Y; Yamamoto N; Osei-Kwasi M; Ofori-Adjei D; Takaku H
Biochem Biophys Res Commun; 2004 Jul; 320(2):544-50. PubMed ID: 15219863
[TBL] [Abstract][Full Text] [Related]
3. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
Peng H; Callison D; Li P; Burrell C
Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of HIV-1 in CEM cells by a potent TAR decoy.
Lee SW; Gallardo HF; Gaspar O; Smith C; Gilboa E
Gene Ther; 1995 Aug; 2(6):377-84. PubMed ID: 7584112
[TBL] [Abstract][Full Text] [Related]
5. Antisense RNA sequences targeting the 5' leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle.
Chadwick DR; Lever AM
Gene Ther; 2000 Aug; 7(16):1362-8. PubMed ID: 10981662
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site.
Han W; Wind-Rotolo M; Kirkman RL; Morrow CD
Virology; 2004 Dec; 330(1):221-32. PubMed ID: 15527848
[TBL] [Abstract][Full Text] [Related]
7. Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1.
Chang HK; Gendelman R; Lisziewicz J; Gallo RC; Ensoli B
Gene Ther; 1994 May; 1(3):208-16. PubMed ID: 7584083
[TBL] [Abstract][Full Text] [Related]
8. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.
Chang LJ; Liu X; He J
Gene Ther; 2005 Jul; 12(14):1133-44. PubMed ID: 15750613
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
[TBL] [Abstract][Full Text] [Related]
10. Complementary large loops determine the rate of RNA duplex formation in vitro in the case of an effective antisense RNA directed against the human immunodeficiency virus type 1.
Homann M; Rittner K; Sczakiel G
J Mol Biol; 1993 Sep; 233(1):7-15. PubMed ID: 8377194
[TBL] [Abstract][Full Text] [Related]
11. Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy.
Duan L; Zhu M; Ozaki I; Zhang H; Wei DL; Pomerantz RJ
Gene Ther; 1997 Jun; 4(6):533-43. PubMed ID: 9231069
[TBL] [Abstract][Full Text] [Related]
12. Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy.
Junker U; Böhnlein E; Veres G
Gene Ther; 1995 Nov; 2(9):639-46. PubMed ID: 8548553
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of HIV-1 replication by cyclopentenone prostaglandins in acutely infected human cells. Evidence for a transcriptional block.
Rozera C; Carattoli A; De Marco A; Amici C; Giorgi C; Santoro MG
J Clin Invest; 1996 Apr; 97(8):1795-803. PubMed ID: 8621762
[TBL] [Abstract][Full Text] [Related]
14. Molecular approaches to inhibit HIV-1 tat expression and functions.
Grossi MP; Caputo A; Zucchini S; Bozzini R; Marconi PC; Manservigi R; Barbanti-Brodano G; Balboni PG
Year Immunol; 1993; 7():199-204. PubMed ID: 8396820
[No Abstract] [Full Text] [Related]
15. Theoretical design of antisense RNA structures substantially improves annealing kinetics and efficacy in human cells.
Patzel V; Sczakiel G
Nat Biotechnol; 1998 Jan; 16(1):64-8. PubMed ID: 9447596
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of a triple combination gene therapy vector inhibiting HIV-1 multiplication.
Asparuhova MB; Barde I; Trono D; Schranz K; Schümperli D
J Gene Med; 2008 Oct; 10(10):1059-70. PubMed ID: 18642399
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
Mautino MR; Morgan RA
Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
[TBL] [Abstract][Full Text] [Related]
18. Altered replication of human immunodeficiency virus type 1 (HIV-1) in T cell lines retrovirally transduced to express Herpesvirus saimiri proteins StpC and/or Tip.
Henderson EE; Tsygankov AY; Merlo JJ; Romano G; Guan M
Virology; 1999 Nov; 264(1):125-33. PubMed ID: 10544137
[TBL] [Abstract][Full Text] [Related]
19. Characterization of antisense RNA-mediated inhibition of SIV replication.
Tung FY; Tung MH
J Med Virol; 1996 Apr; 48(4):321-5. PubMed ID: 8699163
[TBL] [Abstract][Full Text] [Related]
20. Reduction in replication of the human immunodeficiency virus type 1 in human T cell lines by polymerase III-driven transcription of chimeric tRNA-antisense RNA genes.
Junker U; Rittner K; Homann M; Bevec D; Böhnlein E; Sczakiel G
Antisense Res Dev; 1994; 4(3):165-72. PubMed ID: 7849487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
